Drugs / Anti-CD33-CAR-transduced T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02958397 | Oct 2016 → Oct 2019 | myeloid neoplasm | Southwest Hospital, China | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD33-CAR-transduced T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02958397 ↗ |
| Modality | Cell therapy | “CD33-targeted chimeric antigen receptor T(CAR-T) cells” NCT02958397 ↗ |
| Target | CD33 | “CD33-targeted chimeric antigen receptor T(CAR-T) cells” NCT02958397 ↗ |